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Although the advancement of radioimmunotherapy (RIT) has benefitted patients with non-Hodgkin 
lymphoma to a certain degree, additional improvements are needed to further reduce the relapse 
rates. With RIT, malignant cells are selectively killed using tumor-targeting antibodies labeled with 
radioactive isotopes. This technique is especially well-suited for treatment of B cell lymphomas, due 
to their exquisite radiation-sensitivity. While initial responses to therapy often are encouraging, for 
most patients with advanced stage indolent (slow-growing) non-Hodgkin lymphoma and mantle cell 
lymphoma the benefit is unfortunately merely temporary. The reason is spelled MRD, or "minimal 
residual disease", referring to microscopic clusters of treatment-resistant tumor cells that require 
upgraded therapy for complete eradication. For Fred Hutch's Dr. Damian Green, that upgrade 
comprises alpha particle emitting isotopes, or more precisely, the alpha emitter astatine-211. In a 
recent publication in Blood, Dr. Green and colleagues from the Press Lab in the Clinical Research 
Division demonstrated that complete eradication of disease could be achieved in 70% of mice with 
disseminated lymphoma after treatment with astatine-211-labeled antibodies directed against the 
CD20 antigen. Contrastingly, no animals survived in matching control groups. 
This therapeutic success relied on the physical properties of alpha particle radiation. In contrast to 
the more commonly used beta emitting radionuclides, alpha emitters release particles with very high 
energy combined with extremely short range. In general, alpha radiation emitted from astatine-211 
only travels about 50 to 70 µm in tissue, making it ideal for treating microscopic tumors while 
minimizing the exposure to surrounding healthy tissue. Targeted alpha therapy studies have long 
been hampered by production issues and a lack of efficient radiochemical labeling methods, but 
substantial progress has been made in recent years. "Recently, we have been able to generate 
sufficient quantities of short path-length alpha emitting radionuclides to support clinical applications; 
in addition, our collaborators at the University of Washington have discovered a way to provide 
critical stability to alpha particle-labeled monoclonal antibodies," Dr. Green explained. Furthermore, 
he added that in comparison to first-generation RIT beta emitters like yttrium-90 and iodine-131, 
"alpha emitters have greater than 500 times more energy per unit length, and as few as 1 to 5 alpha 
particle emissions can be sufficient to cause irreparable DNA damage and induce cell death." 
In addition to the MRD model, the Fred Hutch research team explored targeted alpha therapy of 
mice with solid lymphoma tumors (approximately 100 mm
3
 at the start of therapy). In this disease 
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setting they saw a radically different outcome; none of the animals were cured, although survival 
time after astatine-211-RIT was prolonged 2–3-fold in comparison with controls. Striking as this was, 
Dr. Green was not all that surprised. "The results confirmed our hypothesis that alpha emitting 
radionuclides would be most effective in micrometastatic or minimal residual disease settings." In 
fact, the outcome validated predictions made through mathematical models that took the features of 
alpha particle radiation into consideration. Depending on the distribution of radiolabeled antibodies 
within the tumor mass, bulky tumors may be more efficiently obliterated using beta radiation; this is 
due to the longer in vivo range of beta particles (up to about 10 mm), which may make up for a 
certain degree of suboptimal targeting. 
"Based on our findings, the best application of targeted alpha emitter therapy is in the clinical setting 
of micrometastatic or minimal residual disease," concluded Dr. Green, who now hopes to translate 
these preclinical results into clinical trials with astatine-211 targeted to B cell lymphomas using anti-
CD20 antibodies. In addition, the findings will support ongoing investigations regarding the use of 
alpha-RIT for treatment of multiple myeloma and other cancers of the blood and bone marrow. 
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Kaplan-Meier survival curves 
demonstrating the efficacy of 
astatine-211-
radioimmunotherapy in a 
minimal residual disease model. 
Disease progression was 
monitored through 
bioluminescence imaging of 
luciferase-transduced Granta 
cells. Mice received 15 µCi of 
astatine-211 via either the anti-
CD20 antibody 1F5 or a non-
binding control antibody 
(HB8181), or no therapy (n = 10 
mice per group). 
